Myriad Genetics (MYD) Stock Statistics & Valuation Metrics

Myriad Genetics has a market cap or net worth of CHF246.21M. The enterprise value is CHF636.61.

Myriad Genetics has ― shares outstanding. The number of shares has decreased by -2.65% in one year.

Myriad Genetics’s return on equity (ROE) is -0.99 and return on invested capital (ROIC) is -10.83%.

The current PE Ratio of Myriad Genetics is ―. Myriad Genetics’s PEG ratio is -0.00859.

In the last 12 months, Myriad Genetics had revenue of 824.50M and earned -365.90M in profits. Earnings per share was -3.96.

In the last 12 months, operating cash flow was 7.70M and capital expenditures -16.30M, giving a free cash flow of -8.60M billion.

Myriad Genetics pays an annual dividend of ―, resulting in a dividend yield of ―

Myriad Genetics upcoming earnings date is Nov 9, 2026, TBA (Confirmed).

Myriad Genetics as a current ratio of 2.49, with Debt / Equity ratio of 69.27%

In the past 12 months, Myriad Genetics has paid -29.20M in taxes.

Myriad Genetics EV to EBITDA ratio is -1.92, with an EV/FCF ratio of -24.77.

Myriad Genetics has CHF115.20M in cash and marketable securities with CHF210.50M in debt, giving a net cash position of -CHF95.30M billion.

Gross margin is 68.83%, with operating margin of -8.22%, and net profit margin of -44.38%.

The average price target for Myriad Genetics is CHF3.23, which is 11.43% higher than the current price. The consensus rating is Hold